Series B - ImmPACT Bio
Investment Firm
Overview
ImmPACT Bio USA is developing novel cell therapies for treating cancer.
Announced Date
Jan 20, 2022
Closed on Date
Jan 21, 2022
Funding Type
Series B
Highlights
Location
United States, North America
Social
Investor Lead
Foresite Capital
Foresite Capital is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.
venBio Partners
venBio Partners is a early_stage_venture and late_stage_venture and post_ipo and seed and venture firm.
Decheng Capital
Decheng Capital is a early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.
Participant Investors
7
Round Details and Background
ImmPACT Bio raised $139855923 on 2022-01-20 in Series B
ImmPACT Bio USA is developing novel cell therapies for treating cancer.
Company Funding History
3
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Aug 18, 2020 |  Series A - ImmPACT Bio | 8 | - | 18.0M |
| Jan 20, 2022 | Series B - ImmPACT Bio | 8 | - | 139.9M |
| Feb 28, 2024 | Grant - ImmPACT Bio | 1 | - | 8.0M |
Recent Activity
There is no recent news or activity for this profile.